Autor: |
R. F. Hwang, Funda Meric-Bernstam, Sarah M. DeSnyder, K. Park, A. S. Caudle, M. Teshome, C. H. Barcenas, Anthony Lucci, Isabelle Bedrosian, Roland L. Bassett, H. M. Kuerer, D. M. Black, E. Fitzsullivan, Kelly K. Hunt, Sarah E. Tevis, Elizabeth A. Mittendorf, Alastair M. Thompson |
Rok vydání: |
2018 |
Předmět: |
|
Zdroj: |
Annals of surgical oncology. 26(3) |
ISSN: |
1534-4681 |
Popis: |
OncotypeDX recurrence score (RS)® has been found to predict recurrence and disease-free survival in patients with node negative breast cancer. Whether RS is useful in guiding locoregional therapy decisions is unclear. We sought to evaluate the relationship between RS and lymph node burden. Patients with invasive breast cancer who underwent sentinel lymph node dissection from 2010 to 2015 were identified from a prospectively maintained database. Patients were excluded if they were clinically node positive or if they received neoadjuvant chemotherapy. RS was classified as low ( 30). The association between RS, lymph node burden, and disease recurrence was evaluated. Statistical analyses were performed in R version 3.4.0; p |
Databáze: |
OpenAIRE |
Externí odkaz: |
|